secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2024-01-25T23:59:59+00:00
Accession:  0001104659-24-006675
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx Q4 revenue $11.3M (+58% YoY); CEO Nadim Yared to retire; FY23 rev $39.3M (+75%)
--------------------------------------------------------------------------------

- Q4 revenue $11.3M (+58% YoY); US HF revenue $10.2M (+70% YoY).
- FY23 revenue $39.3M (+75% YoY); net loss $41.2M ($1.99/share); cash $90.6M.
- Active implanting centers 178 at year-end, up from 106 in prior year.
- CEO Nadim Yared announces retirement; board to conduct succession search; Yared stays until successor appointed.
- FDA approved expanded Barostim labeling; CMS increased outpatient payment to ~$45,000; market opportunity updated to $2.2B annually.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465924006675/0001104659-24-006675-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465924006675/tm244110d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-006675

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer